Strategies for Discussing Potential Adverse Effects of Talquetamab in MM

Early infection incidence in patients with multiple myeloma following treatment with cilta-cel infusion highlights the necessity of toxicity monitoring.

Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.

Updated MAIA trial results reinforce the frontline benefit of daratumumab plus lenalidomide/dexamethasone in transplant-ineligible NDMM.

Beth Faiman, PhD, CNP, discusses reclassifying patients with multiple myeloma, the accelerated approval of teclistamab, and the removal of belantamab mafodotin from the US market.

Median time to sustained worsening of symptoms was 23.7 months with cilta-cel, compared with 18.9 months with SOC.

The association of CAR T-cell therapies with second primary cancers warrants the development and examination of mitigation strategies for these toxic effects.